Potent and selective mTOR inhibitor (IC50
= 2 - 10 nM for mTORC1 and mTORC2). Displays 200-fold selectivity for mTOR over DNA-PK, ATM and hVps34. Induces autophagy in HeLa cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from Whitehead Institute for Biomedical Research.
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
Thoreen CC, Kang SA, Chang JW et al.
J Biol Chem
The pharmacology of mTOR inhibition.
Guertin and Sabatini
Discovery of 1-(4(-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.
Liu et al.
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway.
Peterson et al.
The citations listed below are publications that use Tocris products. Selected citations for Torin 1 include:
Showing Results 1 - 10 of 58